Researchers identified how a brain circuit involving dopamine and GLP-1 receptor impact palatability and hedonic eating.

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

OB-GYNs explain how they're using semaglutide and tirzepatide to treat symptoms of PCOS. The meds help treat weight gain, ...

While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Taking medications like Ozempic and Wegovy may lead to more hair loss than other weight loss drugs, new research found.

“Big picture, the deal aligns with Novo’s strategy to maintain dominance in the obesity space by adding complementary mechanisms to pair with their GLP-1 franchise, and we look forward to more ...

People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

SaveHealth explores what the research says about Ozempic's effects on insulin resistance and related conditions.